The honest bottom line comes first: ARA-290, also called cibinetide, has been reported to increase corneal nerve fiber abundance after about four weeks of daily subcutaneous dosing, but every one of those readings came from small phase 2 trials of systemic small fiber neuropathy rather than from studies of the eye. The cornea served as a convenient imaging window onto body-wide nerve status, and the pain scores that improved alongside it measured burning feet and limb pain, not ocular pain. Nothing in that record is approved, independently replicated, or currently under active registered study.
The corneal nerve fiber gains attributed to ARA-290 come from exploratory secondary endpoints in small phase 2 trials of systemic small fiber neuropathy, and no published study enrolled patients for neuropathic eye pain or tested the peptide as an ophthalmic treatment.
The cornea carries the densest sensory innervation of any tissue in the body and sits behind no opaque barrier, which is the whole reason a laser scanning confocal microscope can resolve individual axons in a conscious patient in a few minutes. What that convenience buys is a proxy: the subbasal fibers being imaged belong to the same class that dies back first in length-dependent small fiber neuropathy, so their loss is read as a stand-in for systemic pathology that would otherwise require a skin biopsy. The stand-in holds only loosely, and sampling is the reason.
Corneal confocal microscopy inspects roughly a sixth of a square millimetre of subbasal plexus per frame at a site that is difficult to relocate at follow-up, which makes it a sensitive but noisy structural signal rather than a hard measurement.
A literature this frequently cited sounds far larger than it is. The corneal evidence for ARA-290 traces back to roughly three phase 2 publications, in which the imaging parameters sat as secondary or exploratory structural endpoints supporting symptom-based primary outcomes. Authorship and sponsorship overlap heavily across them, so the reports share design assumptions and imaging workflows instead of testing each other.
The entire corneal imaging evidence base for ARA-290 rests on a handful of sponsor-connected phase 2 reports with enrollment in the dozens, and no unaffiliated group has published a confirmatory corneal imaging result.
The treatment window constrains everything else here: the pivotal imaging comparison came after roughly 28 days of daily subcutaneous dosing, an interval far shorter than the months to years over which subbasal nerve regrowth is normally measured. Within that window the active arm showed greater corneal nerve fiber abundance than placebo, reported as group-level change in nerve fiber area and related density measures rather than as a distribution of individual response. A structural shift that fast is biologically surprising, and the surprise itself argues for caution rather than enthusiasm.
The placebo-corrected corneal nerve change reached conventional statistical significance in only one of three dose groups among 64 randomized participants, over a 28-day window that sits uncomfortably close to the imaging method's own session-to-session noise floor.
The mechanism is a coherent hypothesis with preclinical support, not a demonstrated human pathway, and that distinction carries real weight against vendor material describing it as settled biology. The proposed chain runs from a heteromeric receptor appearing on stressed tissue, through a shift in immune cell behaviour, to local conditions permitting axons to sprout.
Receptor expression in the human cornea, the immune phenotype shift during human dosing, and the causal link from that shift to measured nerve fiber change are all inferred from rodent and cell work rather than demonstrated in human tissue.
Symptom measurement in these trials came from the small fiber neuropathy toolkit, not from ophthalmology, and reading the item content of those instruments settles the question of what actually improved. They inventory burning feet, shooting limb pain, sweating abnormalities, dry mouth, palpitations, and gastrointestinal disturbance. Ocular pain, photophobia, and foreign body sensation appear nowhere in any dedicated way.
The symptomatic improvement reported in the ARA-290 trials is improvement in body-wide neuropathic symptoms measured by systemic small fiber instruments, and within-participant correlation between imaging change and symptom change was never established as a robust finding.
Ophthalmology treats corneal neuropathic pain as a distinct clinical entity, often called corneal neuralgia and sometimes described informally as pain without stain, where severe burning and photophobia run out of proportion to visible ocular surface damage. Nerve density and pain are not inversely coupled in that setting: regenerating and dysmorphic fibers can be spontaneously active and hyperexcitable, so sparse imaging can accompany intense pain, and recovering fiber counts can accompany unchanged or worsening symptoms. More fibers is not automatically less pain, and that is where the mapping from these trials to eye pain breaks.
| Requirement | Genuine corneal neuralgia trial | ARA-290 published trials |
|---|---|---|
| Enrollment basis | Ocular pain, dry eye, corneal neuralgia | Systemic small fiber neuropathy |
| Primary endpoints | Validated ocular pain and discomfort scales | Body-wide neuropathic pain scores |
| Phenotyping | Topical anesthetic challenge | Not performed |
| Imaging focus | Microneuromas, fiber irregularity | Fiber density and area |
| Safety assessment | Full ophthalmic battery | No ocular-specific plan |
No published ARA-290 trial recruited participants on the basis of ocular pain, dry eye, or corneal neuralgia, so its corneal imaging data cannot support a claim that the peptide treats neuropathic eye pain.
Statistical power colors every other weakness in this corpus. Arms holding roughly sixteen participants produce estimates in which a small real effect and a chance fluctuation look much alike, and small trials that report positive results tend to overstate effect size.
The corneal findings are provisional rather than wrong, and a confirmatory trial would require a single prespecified primary parameter, centralized masked reading with published reliability statistics, enrollment in the hundreds, imaging continued past the end of dosing, and sites with no financial connection to the sponsor.
Within their narrow limits the published reports describe the peptide as generally well tolerated, though the posted registry record for the pivotal trial is less tidy than that phrase suggests. Exposure of a few dozen participants over four weeks under close supervision can surface only common, early, obvious events.
Registry results for the pivotal sarcoidosis trial record serious adverse events in three peptide-treated participants against none on placebo, and absence of observed harm in a few dozen participants dosed for four weeks is weak evidence of safety for an investigational compound with no approved use.
The corneal nerve field already contains an agent that cleared regulatory review, which sets the bar this peptide gets measured against. Route is not a trivial distinction either: a topical agent bathes the ocular surface and can plausibly act on the corneal epithelium and its nerves directly, while a subcutaneous systemic peptide must work through circulating repair signalling that reaches the eye incidentally.
| Criterion | Cenegermin, recombinant human NGF drop | ARA-290 |
|---|---|---|
| Route | Topical eye drop | Subcutaneous injection |
| Studied endpoint | Corneal healing in neurotrophic keratitis | Systemic neuropathic pain, corneal imaging secondary |
| Regulatory status | Approved in multiple jurisdictions | No approval anywhere |
| Evidence tier | Randomized trials with an ocular indication | Exploratory phase 2 endpoints |
Cenegermin holds approval for neurotrophic keratitis on ocular endpoints from randomized controlled trials, autologous serum tears and systemic glucose normalization have small studies reporting subbasal nerve gains over months to years, and ARA-290 sits below all of them at an early exploratory tier with no head-to-head data.
Educational use only. This article describes what the published scientific and clinical literature reports about ARA-290. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
